|
|
Vioxx
Zoll, Kranz and Borgess is currently reviewing claims related to the prescription drug Vioxx (Refecoxib). Vioxx was voluntarily removed from the market by its manufacturer, Merck & Co., in September 2004 due to the significant safety concerns of an increased risk of cardiovascular events. Vioxx is the tradename for the drug Refecoxib, which is a Cox-2 inhibitor.
The Food & Drug Administration (FDA) approved Vioxx in May of 1999 for use in the reduction of pain and inflammation from osteoarthritis, acute pain in adults, and treatment of premenstrual syndrome. The FDA later expanded its approval of Vioxx to include treatment for rheumatoid arthritis in adults and children. Over the last five years, Merck & Co. has engaged in one of the largest sampling programs ever and dedicated millions of dollars to direct marketing and advertising in order to secure a competitive market share. As of 2003, Merck & Co. reported approximately $2.5 billion in sales from Vioxx.
On September 30, 2004, Merck & Co. announced the voluntary withdrawal of Vioxx from the worldwide market. This action was due to safety concerns of an increased risk of cardiovascular events, such as heart attack and stroke. We believe that this recall was long overdue.
Cases filed in federal courts across the country have now been consolidated as multidistrict litigation for discovery purposes. The Judicial Panel on Multidistrict Litigation granted MDL status to the pending and future Vioxx claims, and assigned the case to the Honorable Eldon Fallon in the U.S. District Court for the Eastern District of Louisiana in New Orleans. We are actively involved in the Multidistrict Litigation.
If you or someone you know was on Vioxx and suffered a cardiovascular problem, such as a heart attack or stroke, please contact us to review your case.
Related Links:
|
|
